Whittilong Pharma, a Shanghai-based modified drug development company backed by Shanghai Healthcare Capital (SHC), has reportedly secured over RMB 100 million in a Series B financing round. The funding was provided by multiple family offices.
Established in 2018, Whittilong Pharma specializes in the research and development of a diverse range of pharmaceuticals, including antitumor drugs, analgesics, cardiovascular and cerebrovascular medications, and pediatric drugs. The company’s product portfolio encompasses an array of sophisticated drug delivery systems such as peptide coupled drugs, long-acting injection formulations, nanocrystals, nanomicelles, novel inhalation formulations, and sustained-release formulations. Whittilong Pharma currently has one Category 1 drug and four Category 2 drugs in clinical development, in addition to one generic drug that has received marketing approval.- Flcube.com
